This page shows the latest tiragolumab news and features for those working in and with pharma, biotech and healthcare.
Anti-TIGIT therapy tiragolumab plus Tecentriq offers better progression-free survival improvement after 2.5 years than Tecentriq alone. ... Tiragolumab is also being evaluated in other solid tumours as well as in haematological cancers.
tiragolumab. In January, the US Food and Drug Administration (FDA) issued a BTD for tiragolumab in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) in the first-line setting for
In January, Roche also received a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for a combination of its investigational TIGIT blocker tiragolumab and Tecentriq (atezolizumab) for
of its investigational TIGIT blocker tiragolumab and its PD-L1 inhibitor Tecentriq (atezolizumab). ... According to Roche, tiragolumab is the first anti-TIGIT molecule to win a BTD from the FDA.
More from news
Approximately 0 fully matching, plus 4 partially matching documents found.
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...